ScreenerHero

SLSSELLAS Life Sciences Group, Inc.

NAS · US · Healthcare · Biotechnology · sellaslifesciences.com
15.46USD+11.62%Mkt Cap: 3.12B $P/E: —

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.12B $
Enterprise Value2.57B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.86M $
Revenue/Share—
Last Price15.46 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS81642T2096
Valuation
P/E (Trailing)—
P/E (Forward)-134.00
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B22.64
EPS (TTM)-0.21
EPS (Forward)-0.10
52W Range
1.39097% of range15.88
52W High15.88 USD
52W Low1.390 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-37.90%
ROA-34.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.39M $
CapEx (TTM)—
FCF Margin—
FCF Yield-0.52%
Net Debt-137.61M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio18.83
Quick Ratio18.28
Book Value/Sh0.5920 USD
Cash/Share0.6850 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 8, 2019
Splits
Last Split1:50
Split DateNov 8, 2019
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)32.50 USD
Upside (mean)+110.2%
Target Range30.00 USD – 35.00 USD
$30.00+110.2% to mean$35.00
# Analysts2
Ownership
Shares Out.201.95M
Float201.15M
Insiders0.92%
Institutions36.76%
Short Interest
Short Ratio6.3d
Short % Float28.07%
Short % Out.27.96%
Shares Short54.98M
Short (prev mo.)63.31M
Technical
SMA 5011.53 (+34.1%)
SMA 2006.117 (+152.8%)
Beta2.49
S&P 52W Chg18.16%
Avg Vol (30d)6.58M
Avg Vol (10d)6.03M
Technical Indicators
RSI (14)70.9
MACD0.6454
MACD Signal0.2957
MACD Hist.+0.3497
BB Upper14.44 USD
BB Middle11.74 USD
BB Lower9.048 USD
BB Width45.92%
ATR (14)1.167 USD
Vol Ratio (20d)2.53x